When do you consider cytoreduction in patients with Essential Thrombocytosis?
In a patient with no evidence of bleeding, do you use a platelet cutoff? Do you utilize genomic testing (eg CALR, MPL, JAK2, etc.) to decide on cytoreduction?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Massachusetts General Hospital
Answered on
I consider cytoreduction for patients with ET if they are at high risk of thrombosis based on the R-IPSET score. For intermediate risk patients, I factor in medical comorbidities and symptoms to help decide to initiate therapy. I don't start cytoreduction based on a platelet count alone. If a patien...
Join for free or sign in to see the full answer